Intel Capital invests in Biofourmis, a virtual care company

Intel Corp.'s strategic investment arm has joined Biofourmis' Series D.

Financing in an extension boosts the round's total investment to $320 million.

Biofourmis will use the cash to expand its virtual care products, which will enable high-quality care at home across the continuum.

In addition to digital medicine projects, such as developing digital companion treatments to supplement existing and prospective innovative medications.

Biofourmis announced plans to support clinical trials to accelerate the development of digital treatments in April.

While developing strategic alliances with companies in the digital health and virtual-first care sectors.